10-K: Natera's 2024 10-K Filing: Revenue Surges, Losses Narrow as Genetic Testing Demand Grows

Natera reports significant revenue growth in 2024, driven by increased demand for its genetic testing products, while simultaneously reducing net losses.

Summary

• Natera, Inc., a diagnostics company, released its 10-K filing for the year ended December 31, 2024.
• The company focuses on women's health, oncology, and organ health, offering a range of genetic tests.
• Revenues increased significantly to $1,696.9 million in 2024, compared to $1,082.6 million in 2023 and $820.2 million in 2022.
• Product revenues accounted for $1,685.1 million in 2024, $1,068.5 million in 2023, and $797.3 million in 2022.
• Net losses decreased to $190.4 million in 2024, from $434.8 million in 2023 and $547.8 million in 2022.
• Approximately 3.1 million tests were processed in 2024, compared to 2.5 million in 2023 and 2.1 million in 2022.
• The company's cloud-based distribution model, Constellation, expands access to its molecular and bioinformatics capabilities.
• Natera faces intense competition in the molecular testing market from companies like Labcorp, Myriad Genetics, Quest Diagnostics, Illumina, and CareDx.
• The company is involved in ongoing legal proceedings, including intellectual property disputes.
• Natera relies on a limited number of suppliers, including sole-source suppliers, for laboratory instruments and materials.
• The company is subject to extensive government regulations, including FDA oversight and CLIA certification.
• Natera is committed to sustainability and has established Scope 1, 2, and 3 intensity reduction targets as part of its climate action plan.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While revenue growth is strong and losses are decreasing, there are still significant risks and challenges, including competition, regulatory hurdles, and ongoing litigation.

Positives

• Significant revenue growth driven by increased demand for genetic testing products.
• Substantial reduction in net losses compared to previous years.
• Strong growth in testing volume, indicating increased market adoption.
• Extensive peer-reviewed publications and a strong intellectual property portfolio.
• Positive clinical data supporting the accuracy and reliability of Natera's tests.
• Expansion of in-network contracts with health plans, increasing access to testing for patients.
• Commitment to sustainability and environmental responsibility.

Negatives

• The company has incurred net losses since its inception and anticipates that it will continue to incur losses for the foreseeable future.
• Natera faces intense competition in the molecular diagnostic testing market.
• The company relies on a limited number of suppliers, including sole-source suppliers, for some of its laboratory instruments and materials.
• Natera is involved in ongoing legal proceedings, including intellectual property disputes, which may have an adverse effect on its business.
• The company is subject to extensive government regulations, including FDA oversight and CLIA certification, which may increase compliance costs.

Risks

• Inability to successfully grow revenues for its products or services.
• Inaccurate estimates of total addressable markets and forecasts of market growth.
• Failure to expand, maintain, or obtain third-party payer coverage and reimbursement for its tests.
• Unsuccessful sales, distribution, development, or other partnerships.
• Costly and time-consuming litigation or other proceedings resulting from intellectual property claims.
• Increased compliance risks as a result of rapid growth.
• Adverse impact on revenues if third-party payers withdraw coverage or provide lower levels of reimbursement.
• Substantial costs and delays associated with trying to obtain premarket clearance or approval from the FDA.
• Adverse impact on business, financial results, and prospects due to recent macroeconomic pressures.

Future Outlook

Natera intends to enhance its existing products, expand its product portfolio, and launch new products in the future, focusing on women's health, oncology, and organ health. The company seeks to enable wider adoption of its technology through its global cloud-based distribution model.

Industry Context

Natera operates in the competitive molecular diagnostics market, facing competition from established and emerging companies. The company's success depends on its ability to innovate, demonstrate the value of its products, and secure favorable reimbursement policies.

Comparison to Industry Standards

• Natera competes with companies such as Laboratory Corporation of America Holdings (Labcorp), Myriad Genetics, Inc., Quest Diagnostics Incorporated, Illumina, BillionToOne Inc., BGI, Fulgent Genetics, and Revvity Inc. in the NIPT space.
• In oncology, Natera competes with NeoGenomics, Inc., Invitae Corp., Guardant Health, Inc., Tempus Labs, Inc., Personalis, Inc., Exact Sciences Corp., and Quest.
• In organ health, Natera's primary competitor is CareDx, Inc.
• The company believes that it compares favorably against its competitors based on its core technology, continued investment in generating scientific data, strong commercial teams, and user experience.

Legal Proceedings

• The company is involved in legal proceedings, including intellectual property disputes, testing and test performance, billing, reimbursement, marketing, short seller and media allegations, employment, and other matters.
• In January 2024, a jury verdict of $57 million was awarded against the company in a patent infringement lawsuit filed by Ravgen, Inc.
• In November 2024, a jury verdict of over $292 million was awarded against the company in litigation with Guardant Health, Inc.

Related Party Transactions

• In December 2021, the Company participated along with certain other investors in the series B financing of MyOme, Inc. (MyOme), and purchased preferred shares and warrants in exchange for a cash payment of approximately $4.0 million which was allocated $2.2 million for preferred shares and $1.8 million for warrants.
• In August 2024, the Company participated in a subsequent round of the series B financing and purchased an additional $2.7 million of series B preferred shares at the same valuation as the initial round of financing in December 2021.
• In February 2024, the Company entered into a collaboration and commercialization agreement (the Collaboration Agreement) with MyOme pursuant to which the parties will partner to offer certain genetic testing services to be developed and funded solely by MyOme and overseen by a joint steering committee.

Stakeholder Impact

• Shareholders: Dilution may occur from future equity issuances.
• Employees: Changes in compensation and benefits are possible.
• Customers: Access to innovative genetic testing products may improve patient care.
• Suppliers: Continued reliance on a limited number of suppliers may impact supply chain stability.
• Creditors: Indebtedness may decrease business flexibility and access to capital.

Next Steps

• Continue to enhance existing products and expand the product portfolio.
• Launch new products in women's health, oncology, and organ health.
• Enable wider adoption of technology through the global cloud-based distribution model.
• Generate peer-reviewed clinical evidence for tests.
• Maintain a strong intellectual property portfolio.

Key Dates

Keywords

genetic testing, NIPT, Signatera, Prospera, molecular diagnostics, reimbursement, FDA, oncology, womens health, organ health